Apple’s Record High… And Structure Therapeutics’ CEO On Weight Loss Drugs 6/11/24
CNBC's "Fast Money"
00:00
Discussion on Structure Therapeutics' Weight Loss Drug and Competitiveness
Structure Therapeutics experiences a 50% increase in shares following the positive early-stage data release on their small molecule GLP1 pill for weight loss, with patients showing a 6.2% body weight reduction. The CEO discusses the potential of their oral pill GSPR 1290 as a competitive option against existing products from companies like Lilly and Novo, emphasizing its effectiveness and scalability.
Play episode from 30:45
Transcript
